ArticleJournal of diabetes investigation2026
Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital-based claims database.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
AIMS/
introductionTo evaluate whether sodium-glucose cotransporter 2 inhibitor (SGLT2i) initiation is associated with the risk of urinary tract infection (UTI), with upper UTI and genital infection assessed as secondary outcomes, compared with metformin in patients with immune-mediated inflammatory diseases (IMIDs) and type 2 diabetes. MATERIALS AND
methodsWe conducted a target trial emulation using an active-comparator, new-user design with a Japanese hospital-based claims database from 2014 to 2024. Adults with IMIDs and type 2 diabetes who newly initiated an SGLT2i or metformin were included. The primary outcome was UTI; secondary outcomes were upper UTI and genital infection. Hazard ratios (HRs) were estimated using inverse probability of treatment weighting and weighted Cox proportional hazards models. Prespecified subgroup and interaction analyses further evaluated heterogeneity in UTI risk according to concomitant immunosuppressive therapies.
resultsWe analyzed 1,845 SGLT2i initiators and 1,499 metformin initiators (mean age 71.8 years; 55.4% female). Compared with metformin initiation, SGLT2i initiation was not associated with increased risks of UTI (HR 1.14, 95% confidence interval [CI] 0.84-1.55) or upper UTI (HR 1.28, 95% CI 0.71-2.31). Results for UTI were broadly similar across categories of concomitant immunosuppressive therapies, and interaction analyses showed no evidence of effect modification across these strata, including glucocorticoid dose. The risk of genital infection was higher with SGLT2i initiation (HR 2.31, 95% CI 1.16-4.63).
conclusionsAmong patients with IMIDs and type 2 diabetes, SGLT2i initiation was not associated with increased risks of UTI or upper UTI compared with metformin, although the risk of genital infection was higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.